Your session is about to expire
← Back to Search
MK-7684A for Advanced Cancers
Study Summary
This trial is testing a new cancer drug, given alone or with other anticancer therapies, to see if it is safe and effective in treating people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have both hepatitis B and C.I have endometrial cancer.I agree to follow the study's rules for using birth control.My blood pressure is under control, with or without medication.I have had serious heart problems in the last year.My cancer is advanced and cannot be surgically removed.You have one of the listed types of advanced (unresectable or metastatic) solid tumors, your blood pressure is controlled, if you have HIV it is well managed with medication, and you agree to use contraception if needed.I have not received a live vaccine within the last 30 days.I am currently on medication for an infection.I have had a transplant of an organ or tissue from another person.I have not been treated with lenvatinib before.My cervical cancer is one of the following types: squamous, adenosquamous, or adenocarcinoma.I have been treated for an autoimmune disease in the last 2 years.My HIV is well controlled with medication.My cancer is in the esophagus or where my stomach meets my esophagus.I have been diagnosed with liver cancer (HCC).I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.I am not pregnant, breastfeeding, and if able to bear children, I agree to use contraception.I have previously been treated with specific immune therapy drugs.I have been diagnosed with head and neck squamous cell carcinoma.I haven't had cancer treatment or been in a trial for at least 4 weeks.My cancer can be measured using standard imaging tests.My organs are working well.I had another cancer but was treated successfully and have been cancer-free for 3 years.My cancer in the bile ducts or gallbladder cannot be removed by surgery.
- Group 1: Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin
- Group 2: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)
- Group 3: Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab
- Group 4: Pembrolizumab/Vibostolimab Co-Formulation
- Group 5: Pembrolizumab
- Group 6: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)
- Group 7: Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin
- Group 8: Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel
- Group 9: Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Pembrolizumab/Vibostolimab Co-Formulation been granted authorization by the FDA?
"Although clinical data demonstrates pembrolizumab/vibostolimab co-formulation is safe, it has not yet been tested for efficacy. Thus, our team at Power rated its safety a 2 on the 1 to 3 scale."
Are individuals currently able to apply for this trial?
"Clinicaltrials.gov records show that this research endeavour remains open to volunteer enrolment, having been first posted on the 16th of September 2021 and last edited on November 25th 2022."
To what extent is the Pembrolizumab/Vibostolimab Co-Formulation employed as a medical treatment?
"Pembrolizumab/Vibostolimab Co-Formulation is the preferred medication for treating malignant neoplasms. Moreover, this dual formulation has also demonstrated efficacy in patients suffering from unresectable melanoma, microsatellite instability high, and rectal carcinoma."
To what extent has Pembrolizumab/Vibostolimab Co-Formulation been tested in previous clinical research trials?
"Since 1997, the City of Hope Comprehensive Cancer Center has conducted 3694 clinical trials involving Pembrolizumab/Vibostolimab Co-Formulation. At present, 2429 ongoing studies are occurring in various cities around the world; Houston being one such location."
With what aims has this experiment been designed?
"The primary purpose of this trial is to evaluate Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR over the course of two years. To gauge success, researchers will also assess Duration of Response (DOR), defined as time from confirmed CR or PR until PD or death according to RECIST 1.1 criteria, and Objective Response Rate (ORR). All measurements are evaluated with the aid of an investigator following RECIST standards."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger